Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.

By M. Confalonieri, R. Urbino, A. Potena, M. Piattella, P. Parigi, G. Puccio, R. Della Porta, C. Giorgio, F. Blasi, R. Umberger and 1 more. American Journal of Respiratory and Critical Care Medicine, 2005

701 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Family Practice

View Paper: https://www.semanticscholar.org/paper/33657345f5dc2a54899e0ceeb36065f581a32a7c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

Citations in the corpus

BTS guidelines for the management of community acquired pneumonia in adults: update 2009 (2009, positive): “RCT enrolled 47 patients to placebo versus 7-day hydrocortisone infusion.(330) [II] The trial was stopped early because of reported efficacy of the steroid treatment.”
Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine (2008, background): “Preliminary data suggest that GCs may be of benefit in patients with severe community-acquired pneumonia, liver failure, pancreatitis, patients undergoing cardiopulmonary bypass, and during weaning from mechanical ventilation (7, 10, 11, 75, 96, 115).”
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, background): “In addition, 3 small pilot studies have suggested that there is a benefit to corticosteroid therapy even for patients with severe CAP who are not in shock [284] [285] [286] .”
Guidelines for the management of adult lower respiratory tract infections - Full version (2011, neutral): “[435] Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study RCT 2C)”
Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. (2007, background): “Duration of mechanical ventilation (5 (4-8) vs 7 (6-17); P = 0.”
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. (2007, neutral): “001 I and II 578 (31) 90 (15) 488 (37) 5 (3) 82 (19) III 475 (25) 104 (18) 371 (28) 17 (11) 84 (20) IV 629 (33) 260 (45) 369 (28) 72 (48) 184 (43) V 204 (11) 129 (22) 75 (6) 55 (37) 74 (17) APACHE III 56.”
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America (2019, result): “The first study found a large magnitude of mortality benefit that has not been replicated in other studies, raising concerns that the results overestimated the true effect (170).”
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 (2013, background): “small population [190], and a recent confirmatory RCT revealed reduced hospital length of stay without affecting mortality [191].”